Ecnoglutide

3 papers6 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab
0 on aging of 11 trials, 3 with no results posted

Human trial3

Outcomes

Body weight

downin humans3

3 studies

Ecnoglutide decreases body weight in humans (-12.8% (95% CI, -13.7 to -11.8)).
“At week 20, the least-squares mean percentage change in body weight was -12.8% (95% CI, -13.7 to -11.8) in the ecnoglutide group”
Human trialin adults with obesity2.4 mg20 weeksn = 163
Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study
ADA Scientific Sessions 2026 abstract5 Jun 2026
Ecnoglutide decreases body weight in humans (-9.9 to -15.4% vs -0.3%).
“participants receiving ecnoglutide achieved superior bodyweight reductions of -9.9 to -15.4% from baseline vs -0.3% for placebo (P<0.0001)”
Human trialoverweight or obesity48 weeksn = 664
A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide in Adults with Overweight or Obesity
ADA Scientific Sessions 2025 abstract13 Jun 2025
Ecnoglutide decreases body weight in humans.
“more participants receiving ecnoglutide achieved HbA1c target of ≤6.5% and weight loss targets of ≥5.0% and ≥10.0% than receiving dulaglutide.”
Human trialtype 2 diabetes uncontrolled on metformin52 weeks
A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide vs. Dulaglutide in Adults with Type 2 Diabetes
ADA Scientific Sessions 2025 abstract13 Jun 2025

Liver fat content

downin humans1

1 study

Ecnoglutide decreases liver fat content in humans.
“Ecnoglutide also led to improvements in cardiometabolic indexes including lipid profile and liver fat content.”
Human trialoverweight or obesity48 weeksn = 664
A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide in Adults with Overweight or Obesity
ADA Scientific Sessions 2025 abstract13 Jun 2025